Last reviewed · How we verify

Synthon BV — Portfolio Competitive Intelligence Brief

Synthon BV pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Glatiramer Acetate (GTR) Glatiramer Acetate (GTR) phase 3 Immunomodulator; synthetic polypeptide T cell receptor (indirect); myelin-reactive B and T cells Immunology; Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Biocad · 1 shared drug class
  2. Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Synthon BV:

Cite this brief

Drug Landscape (2026). Synthon BV — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/synthon-bv. Accessed 2026-05-13.

Related